A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

Inclusion Criteria: * Body mass index (BMI) between 18.5 and 29.9 kg/m2, inclusive * No clinically significant findings from medical history, 12-lead ECG, and vital signs and laboratory evaluations * Negative test for selected drugs of abuse * No infection with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) * Sterile or agree to use an adequate contraception method * Historically able to produce a minimum of 1 bowel movement per day Exclusion Criteria: * Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance unless approved by the Investigator * History of stomach or intestinal surgery or resection (including a cholecystectomy) that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and/or hernia repair will be allowed * History of Gilbert's Syndrome * History of diabetes mellitus and/or elevated fasting glucose at baseline * History or presence of an abnormal ECG * History of alcoholism or drug addiction within 1 year prior Check-in * Participation in more than one other radiolabeled investigational study drug trial within 12 months prior to Check-in * Exposure to significant radiation within 12 months prior to Check-in study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to Check-in * Use of any tobacco-containing or nicotine-containing products within 6 months prior to Check-in * Participation in any other investigational study drug or biologic agent trial in which receipt of an investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to Check-in * Use of any prescription medications/products within 14 days prior to Check-in